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In efforts to address the rising burden of diabetes 
and hypertension,[1-6] some provincial departments 
of health in South Africa (SA) are implementing 
population-level screening programmes for 
cardiovascular risk factors, including diabetes 
and hypertension. In addition, the National Ministry of Health 
included screening for diabetes and hypertension as part of the 
HIV counselling and testing campaign that commenced in April 
2010. Screening seeks to identify apparently healthy individuals who 
have, or are at increased risk of, cardiovascular disease but do not 
yet manifest symptoms, with the aim of instituting treatment and 
impacting favourably on the disease course.[7]
Although screening for diabetes and hypertension has the 
potential to improve health, its effectiveness depends on whether 
blanket screening (population-wide screening for every individual, 
irrespective of gender, age group and health conditions), targeted 
screening (screening targeted at individuals known to be at increased 
risk for certain conditions/diseases), or opportunistic screening 
(screening provided at point of care for other related conditions) is 
undertaken.[1]
Population-wide screening programmes are associated with 
high implementation costs, wastage of resources due to ineffective 
programmes, and inconveniences and psychological distress resulting 
from false-positive results.[7] To ensure implementation of screening 
interventions with population-wide benefits, and that are clinically 
effective and cost-effective, any screening method requires evidence 
of its effectiveness.[7,8]
Since systematic reviews of randomised controlled trials are 
the gold standard of evidence for the effectiveness of healthcare 
interventions, we analysed current systematic reviews that have 
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evaluated the effects of blanket (population-wide) screening for 
diabetes and hypertension, compared with targeted or opportunistic 
screening, or no screening. In this context, it bears noting that 
systematic reviews use explicit, systematic methods to collate all 
existing studies that meet prespecified eligibility criteria, and assess 
the validity of the findings in included studies, to address a clearly 
stated objective or research question.[9]
Methods
Criteria for study selection
We included systematic reviews of population screening (also called 
blanket or community-wide screening) for diabetes mellitus and/
or hypertension, using any type or combination of screening tests 
implemented in the general healthy population. These interventions 
could have been compared with targeted, opportunistic or no 
screening.
Our primary outcomes included all-cause mortality and diabetes- 
and hypertension-related morbidity. Our secondary outcomes 
of interest included uptake of the screening, incident cases of 
hypertension and correctly diagnosed diabetes, impact on the 
healthcare services, cost-effectiveness and quality of life.
Searching for systematic reviews
We searched the electronic databases MEDLINE (PubMed), the 
Cochrane Library, the TRIP database, McMaster Health Evidence.
org, the EPPI library and the Campbell Library up to August 
2013. We used a comprehensive search strategy, without language 
restrictions, to identify all existing relevant systematic reviews. 
Reference lists of included studies were also examined for any other 
relevant reviews.
Study selection, data extraction and analysis
Two authors (SD and YA) independently screened search results and 
extracted data from eligible studies. Disagreements were resolved by 
discussion with a third author (TK). The methodological quality of 
included reviews was evaluated using AMSTAR, an 11-item validated 
tool.[10] Each item on AMSTAR is rated as yes (clearly done), no 
(clearly not done), unclear or not applicable. Each item rated ‘yes’ 
was awarded one point, and points were summed to calculate a 
total score. Total scores of 0 - 4 indicated low quality, 5 - 8 moderate 
quality, and 9 - 11 high quality.[11] Information from the included 
reviews was summarised narratively.
Results
The database search retrieved 875 records. Two completed 
systematic reviews and one ongoing review were included: 
Krogsboll et al.[12] assessed the benefits and harms of general health 
checks in adults, compared with no health checks, on morbidity 
and mortality, and Ebrahim[13] compared the effectiveness of 
more and less intensive methods of detecting hypertension. Both 
reviews involved adult participants and were conducted in high-
income settings. The third ongoing study involves a protocol of a 
Cochrane review that plans to assess the effects of screening for 
type 2 diabetes on reducing morbidity and mortality, compared 
with no screening.[14] Table 1 summarises the characteristics of 
these three reviews.
The Krogsboll and Ebrahim reviews were of high and moderate 
quality (AMSTAR scores 9/11 and 7/10, respectively). In the case of 
Ebrahim, it was unclear whether unpublished as well as published 
studies had been searched for. Neither review reported on publication 
bias, or assessed possible conflict of interest in the studies they 
included.
Effects of interventions
Ebrahim[13] did not address screening for diabetes. Krogsboll et al.[12] 
assessed interventions that screened for many diseases, including 
diabetes and hypertension. Table 2 summarises the results of both 
these reviews.
Effects on mortality and morbidity
Krogsboll et al.[12] found no effects of general health checks on 
mortality, either total (risk ratio (RR) 0.99, 95% confidence interval 
(CI) 0.95 - 1.03; meta-analysis of nine studies, 155 899 participants, 
I2 = 0%) or cardiovascular (RR 1.03, 95% CI 0.91 - 1.17; meta-analysis 
of eight studies on 152 435 participants, I2 = 64%). The duration of 
follow-up was 4 - 22 years, varying within each trial for different 
outcomes. Health checks compared with no health checks had no effect 
on morbidity (coronary heart disease, stroke or myocardial infarction).
Ebrahim[13] did not evaluate the effect of screening for hypertension 
on mortality or morbidity.
Uptake of screening
Ebrahim[13] found that less rigorous studies, or those conducted in 
areas with poor healthcare coverage, showed that intensive screening 
methods (e.g. door-to-door) were more effective at increasing 
coverage of the population compared with less intensive methods 
(e.g. routine case finding). However, in well-conducted trials, or in 
populations with reasonable access to healthcare, this was not the 
case.
Krogsboll et al.[12] did not assess uptake of screening.
Detection of incident cases of hypertension and diabetes mellitus
Ebrahim[13] found no difference in the yield of unknown hypertensive 
patients through screening compared with routine case finding. 
Krogsboll et al.[12] reported that health checks are likely to increase 
the number of diagnoses, but noted that this outcome was poorly 
documented in most studies.
Impact on the health service
Krogsboll et al.[12] found that general health checks had no effect on 
hospital admission rates, number of people admitted to the hospital 
once or more, number of days in hospital, or number of physician 
visits.
Cost-effectiveness and quality of life
Neither review reported on cost-effectiveness or quality-of-life 
outcomes.
Discussion
We found two completed systematic reviews that addressed some 
aspects of our question regarding population screening v. targeted, 
opportunistic or no screening for diabetes and hypertension. 
Krogsboll et al.[12] found that health checks for the general population 
did not reduce general or cardiovascular-related morbidity and 
mortality, and results were poorly reported for the effect on new 
diagnoses and the impact on the healthcare system. Ebrahim[13] 
found increased coverage with intensive screening in areas with 
poor healthcare coverage. We also found an ongoing review, the 
aim of which is to assess the efficacy of screening for type 2 diabetes 
compared with regular care in reducing morbidity and mortality 
related to diabetes.
These findings urge caution regarding the implementation 
of population-based screening interventions. Evidence from a 
systematic review of economic studies assessing the cost-
effectiveness of interventions to prevent and control diabetes 
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Table 1. Characteristics of included studies
Krogsboll et al.[12] Ebrahim[13] Woolthuis et al.[14] (protocol)
Objectives of the review To quantify the benefits and 
harms of general health checks 
with an emphasis on patient-
relevant outcomes such as 
morbidity and mortality, rather 
than on surrogate outcomes 
such as blood pressure and 
serum cholesterol levels
To determine the most 
effective methods of 
detecting hypertension, 
improving patient adherence 
with treatment, improving 
control of blood pressure, 
and improving professional 
compliance with standards 
of good practice
To determine the efficacy of screening 
for type 2 diabetes in reducing morbidity 
and mortality associated with diabetes 
compared with no screening. Secondary 
objectives include assessing the effects of 
screening for type 2 diabetes on adverse 
events, healthcare consumption, quality of 
life, and costs.
Date of last search July 2012 July 1996 N/A
Study designs included 
and number of studies 
included
14 RCTs 4 RCTs, 5 quasi-
experimental comparisons 
with contemporary control 
groups, and 2 before-and-
after studies
This review will include only randomised 
controlled trials with a minimum duration 
of 3 months. 
Participant characteristics Adults, regardless of gender 
and ethnicity, in the general 
population or participants 
within a narrow group (e.g. 
employees of a company)
Age ranged from ≥16 years 
to adults of all ages.
This review will include people without 
known diabetes mellitus. The authors will 
assess the precise diagnostic criteria from 
the report, or from the authors in case there 
are missing data. 
Setting High-income countries 
Primary care or community 
High-income countries 
(England, Canada, Wales, 
Scotland)
No specific setting mentioned in the 
protocol.
Intervention features General health checks (defined 
as screening for more than 
one disease or risk factor in 
more than one organ system, 
whether performed only once 
or repeatedly) compared with 
no health checks. They included 
trials that included lifestyle 
interventions, such as advice on 
diet, smoking and exercise, in 
addition to the screening. The 
interventions could have been 
administered by doctors, nurses, 
or other health professionals. 
Interventions comparing 
more intensive screening 
methods for detection 
of hypertension (e.g. 
nurse screening, home 
blood pressure screening, 
housewife or door-to-door 
screening) with less intensive 
methods (e.g. usual care, 
routine health services check 
or case-findings, targeted 
screening, computer doctor 
prompts)
This review will include any studies of 
diabetes screening, including mass, targeted 
and opportunistic screening approaches, 
that use the fasting plasma glucose or 
the 2-hour plasma glucose as a screening 
test, individually or in combination. This 
includes studies using stepwise screening 
procedures, for example questionnaires or 
database selection, followed by those two 
tests.
Comparison interventions will be diagnosis 
of type 2 diabetes during regular care.
Outcomes assessed Primary: All-cause mortality, 
disease-specific mortality 
(cardiovascular and cancer 
mortality)  
Secondary: Morbidity 
(myocardial infarction), new 
diagnosis (total and condition 
specific), admission to hospital, 
disability, patient worry, self-
reported health, number of 
referrals to specialists, number 
of non-scheduled visits to GP, 
number of additional diagnostic 
procedures due to positive 
screening tests, new medications 
prescribed and frequency and 
type of surgery, absence from 
work
Coverage of the population 
achieved and the detection 
rates of new and known 
hypertensive patients
Primary: Incidence of type 2 diabetes (as 
diagnosed at the time of the diagnosis with 
prevailing diagnostic criteria), diabetes-
related mortality (myocardial infarction, 
stroke, peripheral vascular disease, renal 
disease, hyper- or hypoglycaemia or sudden 
death), total mortality, all morbidity and 
diabetes and cardiovascular morbidity 
(vascular complications, neuropathy, 
retinopathy, nephropathy, erectile 
dysfunction, amputation)
Secondary: Adverse events, healthcare 
consumption (e.g. use of medication, 
number of consultations), quality of life, 
and costs.
Outcomes will be assessed in the short (3 - 
6 months), medium (6 - 12 months) or long 
term (>12 months)
N/A = not applicable; RCT = randomised controlled trial; GP = general practitioner.
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further emphasises this.[15] In this review, three cost-effectiveness 
studies, one of universal opportunistic screening for undiagnosed 
type 2 diabetes compared with targeted screening for those with 
hypertension, and two of universal opportunistic screening for 
undiagnosed type 2 diabetes with ensuing treatment compared 
with no screening in a US population aged ≥45 years, showed 
that universal opportunistic screening was not cost-effective. 
These cost-effectiveness studies also showed that screening proved 
cost-effective only when it targeted persons with additional risk 
factors, such as hypertension, or of specific ethnicities, e.g. African 
Americans aged 45 - 54 years.
The lack of an effect of general health checks on the healthcare 
system was surprising, as screening is expected to lead to increased 
use of healthcare services, to confirm diagnosis and initiate treatment 
as necessary. Only one trial, conducted in a high-income setting 
and included in the Krogsboll review, reported an increase in new 
diagnoses with general health checks compared with no health 
checks; it is possible that most cases identified in this way were 
known cases that did not have an additional impact on the health 
system.
Overall completeness, quality and applicability of 
evidence
Neither of the included reviews report on all the specified out-
comes. Ebrahim’s[13] literature search was conducted in 1996, 
and is out dated and likely to have missed important new trials 
addressing the question. The trials included in the reviews were 
conducted in high-income settings, potentially rendering their 
results inapplicable to the lower- or middle-income settings that 
characterise SA. Krogsboll  et al.[12] did not assess screening of 
diabetes and hypertension specifically, but rather screening for 
multiple diseases or risk factors, including diabetes or hypertension. 
The results of these interventions may differ from those addressing 
only hypertension or diabetes.
Conclusion
Screening interventions should be selected on the basis of evi dence of 
their effects in terms of clinical and healthcare system outcomes. This 
is particularly important where under-resourced health services are 
already pressurised to provide care for chronic management of both 
infectious and non-communicable diseases.
There is insufficient evidence from currently available systematic 
reviews to confirm a beneficial effect of blanket screening for 
hypertension and/or diabetes compared with other types of screening 
methods in low- and middle-income settings. Scarce resources are 
being mobilised to implement a mass screening intervention for 
diabetes and hypertension without adequate evidence of its effects.
A systematic review is needed to consider the outcomes of clinical 
effectiveness, cost-effectiveness and impact on the healthcare system 
overall of screening strategies, especially in lower- and middle-income 
Table 2. Summary of the results of the included completed reviews
Krogsboll et al.[12] Ebrahim[13]
Primary outcomes
Effects on mortality Total mortality: RR 0.99 (95% CI 0.95 - 1.03); meta-analysis of 9 
studies, 155 899 participants, I2 = 0%
 Cardiovascular mortality: RR 1.03 (95% CI 0.91 - 1.17); meta-
analysis of 8 studies on 152 435 participants, I2 = 64%)
NR
Effects on morbidity Health checks had no effect on morbidity in terms of actual 
illness, but they may increase the number of people diagnosed 
with elevated risk factors.
NR
Secondary outcomes
 Effects on uptake/
coverage of 
screening
NR Results synthesised narratively. More intensive 
screening methods (e.g. door-to-door) were more 
effective at increasing coverage if studies were 
done in areas where coverage was likely to be poor 
(e.g. poor black people in US housing blocks) 
or with less rigorous BAS. Intensive screening 
did not increase coverage greatly in trials that 
were well conducted or done in populations with 
reasonable access to healthcare. 
 Effect on incident 
cases diagnosed
Results synthesised narratively.
 General health checks likely to increase the number of new 
diagnoses, but these results were poorly reported in most trials.
More intensive screening had no effect on the 
detection rates, or yield of unknown hypertensive 
patients, compared with routine case finding. 
 Effects on health 
services
Health checks had no effects on admission rates, number of 
people admitted once or more, or number of days in hospital, 
when compared with no health checks. There were also no 
effects on physician visits.
NR
 Process evaluation 
data/cost-
effectiveness results
NR NR
Quality of life NR NR
NR = not reported; BAS = before-and-after studies.
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